United Therapeutics

3D bioprinting of tissues and organs

Posted on Updated on

According to Yehiel Tal, the Chief Executive Officer of CollPlant, “This fund raising is intended to support the advancement of our pipeline in the fields of medical aesthetics and 3D bioprinting of tissues and organs. We are now focused on facilitating our development programs of dermal fillers and regenerative breast implants. Our collaboration with United Therapeutics, which is using our BioInk technology for 3D printing lungs, is progressing, and we continue to expand our business collaborations with large international healthcare companies that seek to implement our revolutionary regenerative medicine technology. We are very pleased to have entered into this transaction with Mr. Sagi and the other investors.”

 

CollPlant Biotechnologies Raising $5.5 Million

Advertisements

This entry was posted in 3D Print Biotechnology and medicine articles, 3D print medical device manufacturer, 3D Printer material types, 3D Printer Patents, Research and Innovations, 3D Printing and healthcare, 3D Printing for saving humanity, 3D Printing in Medicine and Health, 3D Printing Industry News and trends, 3D printing material learning and exploring, 3D Printing News Alert, 3D Printing possibilities for future, 3D Printing research and education, 3D Printing with Nanomaterials, Artificial Intelligence, Virtual Reality, Robotics, Oculus, 3D Scientific Inquiry and Research, Biocompatibility tests for 3D printing, Design: Design, Grant and funding for 3D printing, Learn how 3D print (Medical), SV3DPrinter solutions and prediction for 3d Printing market, SV3DPrinter's 'Must see posts', SV3DPrinter.com Policy, SV3DPrinter’s vision for future 3D printers and tagged , , , , , , , .